source of signs? You do realize you can copy links to posts? Either way, you have limited credibility without a source
Here is 1 article. http://m.seekingalpha.com/article/2669615-analyzing-antares-pharma-q3-2014-earnings
Two Vibex (auto injector, single shot disposables) products Vibex ® Epi filed with FDA – launch June 2015 pending FDA approval – Antares receives margins on device sales, and mid to high single digit % royalty on overall product sales – Antares to manufacture and ship substantial device quantities early 2015 – Pending FDA approval, Teva is seeking an AB rating From antares investor presentation.
"The AB Epi Pen Vibex injector being developed with Teva will be the next prominent product. The final amendment to the ANDA will be made in December. Antares is optimistic that it will receive an AB rating and will be a material revenue generator. They will start filling the pipeline in early 2015." -Antares: Highlights of CEO’s Presentation at Piper Jaffray Conference (ATRS, Buy, $2.46) POSTED by LARRY SMITH on DEC 4, 2014
They will ship pre-launch quantities of for the AB Epi Pen Vibex Auto injector in 1H, 2015 and the full launch will begin after June 22, 2015.
http://seekingalpha.com/article/2740165-generic-epipen-could-give-these-2-stocks-a-jolt-of-adrenaline
any truth to us launching a generic Advair in the HFA formulation in summer of 15 or 16 maybe 17 ??? I have heard different scenarios. Advair is the 5th most rescribed drug in the world.